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Abstract
Background: The potential harm of medicinal herbs has been recently observed following herbal toxicity studies
after ingestion of polyherbal remedies. This was the rationale for the food and drug regulatory agency decision for
thorough safety evaluation of herbal medicines. Androgenic, antipyretic, analgesic and anti-inflammatory potentials
as well as chemical compositions of extracts of massularia acuminata, terminalia ivorensis, anogeissus leiocarpus and
macuna pruriens respectively have been documented. Thus, Bon-santé cleanser® (BSC) is formulated from these
medicinal plants with the intention to boost body hormones and energizes the body. Considering the wide usage
of BSC, we investigated on its safety in male Wistar rats.
Methods: Thirty-two male Wistar rats weighing 201.9 ± 7.5 g were grouped into four treatment groups of eight per
group. Group I, (control) received distilled water (10 ml/kg). Groups II-IV received 250 mg/kg, 500 mg/kg and
1000 mg/kg of BSC per oral respectively. Each group was treated for sixty days.
Results: Acute toxicity test, in male Wistar albino mice, showed that LD50 was 600 mg/kg via i.p. while 4 g/kg was
nonlethal after oral administration in mice. Hepatic and renal biomarker enzymes were unaltered in all rats.
Increased in PCV (p <0.05) was observed at 500 mg/kg. BSC modulates antioxidants biomarkers following
sub-chronic administration and increased serum Na+ (p >0.05). BSC at 1000 mg/kg caused mild inflammation of the
liver and heart but not kidneys histologically.
Conclusions: BSC has been found to be relatively safe in Wistar rats. Although, our findings indicate that herbal
therapy with BSC should be done with caution as a mild alteration in the liver and heart architectures were
observed.
Keywords: Polyherbal, Bon-santé cleanser®, Acute oral and intraperitoneal toxicity, Herbotherapy, Safety study
Background
Up to now, Africa still provides a non-negligible contribu-
tion to overall complementary and alternative medicines
despite the fact that traditional medical practitioners have
been using crude drug extracts for several years [1–4].
Thus, there is rationale in investigating herbal toxicity
within the African health care system [5, 6], given that a
sizable part of our population regularly use them. Since
the majority of these products have not been rigorously
screened, scientific studies on their uses and toxicological
profile will open up new vistas of rational usage of these
herbal preparations [5, 7, 8].
Bon-santé cleanser® (BSC) is a marketed polyherbal
formula manufactured by Dabiron Natural Life Care in
Nigeria. BSC comprises of different constituents as fol-
lows: anogeissus leiocarpus (DC., family Combretaceae),
terminalia ivorensis (A. Chev.), massularia acuminata
(G.Don,) Bullock ex Hoyle and macuna pruriens (L.,) DC
(fabaceae). formulated into capsule. It is interesting to
note that the androgenic, antipyretic, analgesic and anti-
inflammatory potentials of the extracts of the aforemen-
tioned medicinal plants have been documented [9–16].
And recently, Oriola et al. [17] reported a new bioactive
thiophenolic glycoside from the leaf of M. acuminata in
favour of the antibacterial activities [18] and androgenic
potentials [19] as well as pro-sexual effects [16]. Ponou
et al. [20, 21] demonstrated the present of a dimeric
antioxidant and cytotoxic triterpenoid saponins from T.
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ivorensis and have also synthesized a novel 3‐Oxo‐and 3,
24‐Dinor‐2, 4‐secooleanane‐Type triterpenes from this
plant. Olugbami et al. [22] using an in vitro study have
also unveiled the antioxidant potential, phenolic and flavon-
oid contents of extract of A. leiocarpus while Amadu et al.
[23] reported the cytotoxic activity of the same against
Ehrlich Ascites Carcinoma cells. Study by Hamzaoui et al.
[24] has successfully shown efficient fractionated yields that
contained triterpenes, ellagic acid derivatives, flavonoids
and phenolic compounds from A. leiocarpus. Another rec-
ognition strategy based on 13C NMR used by Hubert et al.
[25] achieved seven constituents natural metabolites in a
crude A. leiocarpus. In addition, Josephine and Janardhanan
[26] and Perumal et al. [27] have dissected separately the
proximate composition, seed protein fractions, amino acid
composition, minerals and anti-nutritional factors in M.
pruriens with high contents of crude protein and crude
lipids. Interestingly, aside L-3,4-dihydroxyphenylalanine, M.
pruriens was found to be rich in minerals such as K, Mg
and P. [26, 28].
The androgenic potential of aqueous extract of massu-
laria acuminata was reported in male rats [10, 16].
Similarly, Shuklaet al. [11] demonstrated improved male
fertility of macuna pruriens by its action on the
hypothalamus-pituitary-gonadal axis. More so, anogeis-
sus leiocarpus and T. ivorensis were explored and veri-
fied for their local uses as antipyretics, analgesics and
anti-inflammatory effects in rodents [9, 12–14]. A. leio-
carpus also showed endothelium-independent and
endothelium-dependent vasorelaxation action [15]. The
pharmacological activities of M. acuminata, T. ivorensis,
A. leiocarpus and M. pruriens have been adduced to be
due to the presence of glycosides [16], dimeric antioxi-
dants [20, 21], phenolics [22] and flavones respectively
[26, 27]. Considering the wide usage of BSC, coupled
with the warning by the National Agency for Food and
Drug Administration and Control (NAFDAC) that it has




The study was carried out in the Department of Pharma-
cology, University of Lagos, Lagos Nigeria. Bon-santé
cleanser® was obtained from Dabiron Natural Life Care,
Nigeria. Thiobarbituric acid (TBA), Ellman’s reagent
(DTNB) and 1-Chloro-2, 4,- dinitrobenzene (CDBN) were
purchased from Sigma Chemical Company (USA). Re-
duced glutathione (GSH), Metaphosphoric acid and
Trichloroacetic acid (TCA) were purchased from J.I. Baker
(USA). Bovine serum albumin fraction V (BSA) was pur-
chased from SRL, India. All other chemicals and reagents
used were of analytical grade.
Method of extraction and preparation of the final
formulation
BSC was obtained directly from the Dabiron Natural Life
Care in Nigeria. It was assigned Batch number 002 and
listed with number A7-5321 L by the National Agency for
Food and Drug Administration and Control (NAFDAC).
BSC contains Anogeissus leiocarpus (DC., family Combre-
taceae) Guill & Perr., Terminalia ivorensis (A. Chev., fam-
ily Combretaceae), Massularia acuminata (G.Don, family
Rubiaceae) Bullock ex Hoyle and Macuna pruriens (L.,
family leguminosae) DC. in the ratio 4:2:1:1 respectively.
The extraction and formulation procedures complied with
the regulatory manual of NAFDAC. In this context, a sin-
gle capsule of BSC (total content 442 mg) was dissolved in
distilled water (80 mg/ml) which was administered via oral
gavage according to standard toxicological guidelines.
Animals
Albino rats of the Wistar strain weighing between
150–300 g were purchased from the animal house of
the Redeemers University, Ogun State, Nigeria. The
rats were housed under controlled conditions in the
experimental animal handling facility of the College of
Medicine, University of Lagos, Nigeria. The experimental
animal room had a 12 h light/12 h dark schedule and
maintained at a temperature of 22 ± 3 °C throughout the
study. Animals were fed with commercially available rat
pelleted diet (Ladoke Akintola Growers Mash, Nigeria)
and were allowed access to water ad libitum throughout
the period of the experiment. The experimental protocols
were approved by the Institutional Animal Care and Use
Committee, Department of Pharmacology, Therapeutic
and Toxicology, College of Medicine, University of Lagos.
Animals were certified fit for the experiment by the Insti-
tution’s Animal Health Officers before the commence-
ment of the study. Beddings were changed on alternate
days and the animals were sacrificed in a humane manner
at the end of the experiment by cervical dislocation. The
investigation conforms to the Guide for the Care and Use
of Laboratory Animals published by the U. S. National In-
stitutes of Health (NIH Publication No. 85-23, revised
1996)” for studies involving experimental animals and the
procedures as documented by Kilkenny et al. [29] for
reporting animal research.
Experimental design
Acute oral toxicity test
Thirty (30) male Wistar mice (average weight, 20 g) in
separate cages were randomly divided into six groups
and allowed to acclimatize for two weeks. Graded doses
of BSC of 250, 500, 1000, 2000 and 4000 mg/kg were ad-
ministered to the animals orally and were allowed access
to water ad libitum. The control group was administered
0.1 ml distilled water orally. The Mice were observed for
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24 h post-treatment for mortality, behavioral changes in-
cluding hyperactivity, attempting circular movement,
leaning on hind limbs, increased feeding habit, scratch-
ing of lower jaw immediately after treatment and 2 h
after treatment, writings, and agitation. All the animals
were further monitored for 14 days post administration.
Acute intraperitoneal toxicity test
Thirty (30) male mice (average weight, 20 g) placed in sep-
arate cages were randomly divided into five groups.
Graded doses of BSC of 200, 400, 800 and 1600 mg/kg
were administered intraperitoneally. The control group
was administered 0.1 ml of distilled water. The Mice were
observed 24 h post-treatment for mortality, behavioural
changes, and signs of toxicity. At 200 mg/kg (i.p.) of BSC,
animals showed agitation, climbing, gripping, hyperphagia,
leaning on hind limbs and circular movement. Animals
that received doses of 400 mg/kg and above showed signs
of restlessness, weakness, flattened abdomen, and tears
after 2 h of administration. It was observed that at about
6th–10th hour, body weight reduced and most animals
shivered. Mortality was observed and recorded for each
group of animals following 24 h of administration. All ani-
mals were further monitored for 14 days post administra-
tion. The Median Lethal Dose was estimated according to
the method of Finney [30].
Subchronic study
Thirty-Two (32) adult male Wistar rats weighing between
150–300 g were divided into 4 groups of 8 rats per group.
Group I, the control group, received 10 ml/kg of distilled
water daily. The treated animals received only BSC.
Groups II, III and IV were administered 250 mg/kg,
500 mg/kg and 1000 mg/kg of BSC respectively. The rats
were weighed weekly throughout the course of the experi-
ment. The animals were closely observed for behavioural
changes as aforementioned.
Collection of blood samples and tissues for assays
Sub-chronic administration of BSC in experimental rats
was for 60 days. Twenty-four (24) hours following the
last administration, blood samples were obtained by ocu-
lar puncture into bottles treated with anticoagulants
which were either lithium heparin or ethylenediamine-
tetraacetic acid (EDTA). The animals were sacrificed by
cervical dislocation. The anticoagulated blood samples
were centrifuged at 4200 rpm for 5 min to separate out
the plasma from which all biochemical assays were
carried out. The liver, kidney, heart and brain were all
harvested, weighed and were homogenized in four vol-
umes of buffer solution (0.1 M, pH 7.4). A portion of
each organ was taken out for histological studies. The
remaining was weighed and homogenized for biochem-
ical assays.
Biochemical assays
Liver and renal function tests Plasma levels of aspar-
tate aminotransferase (AST) and alanine aminotransfer-
ase (ALT) were determined following the principle
described by Reitman and Frankel [31] while the alkaline
phosphates (ALP) was carried out according to the
method described by Roy [32] to assess liver function.
Renal function was assessed by measuring plasma cre-
atinine (CREA) levels and blood urea nitrogen (BUN)
was assayed following the method of Fossati et al. [33]
and Skegg’s [34].
Proteins and uric acid In order to assess the synthetic
function of the liver, total serum protein (TP) and albu-
min (ALB) concentrations were determined according to
the principles based on the Biuret reaction [35] and bro-
mocresol green reaction [36] respectively. Uric acid
(UA) levels were determined according to the methods
of Fossati et al. [37].
Lipid profiles Total Serum cholesterol (TC) and Triglycer-
ide (TG) concentrations were estimated following the
method described by Trinder [38] by using commercial kits
obtained from Randox Laboratories Ltd (Crumlin, UK).
High-Density Lipoprotein (HDL) was estimated according
to Warnick and Albers [39] while serum low-density lipo-
protein (LDL) was calculated using Freidewald formula [40].
Antioxidants and oxidative stress The method of
Beutler et al. [41] was followed in estimating the level of
reduced glutathione (GSH). Glutathione-S-transferase
(GST) activity was determined according to Habig et al.
[42]. The level of superoxide dismutase (SOD) activity
was determined by the method of Misra and Fridovich
[43]. Catalase activity was determined according to the
method of Sinha [44]. Lipid peroxidation was deter-
mined by measuring the formation of thiobarbituric acid
reactive substances (TBARS) according to the method of
Varshney and Kale [45].
Hematological assessments
Packed Cells Volume (PCV), Hemoglobin (Hb), Platelet
(PLT), Total White Blood Cell Count (TWBC) were de-
termined using a fully automated haematology analyzer
(Pentra-XL 80, Horiba ABX, USA).
Serum electrolytes
Sodium ion (Na+), Potassium ion (K+), Chloride ion (Cl−),
total Calcium ion (tCa2+) and intracellular Calcium ion
(iCa2+) were determined in serum using a Flame Photom-
eter (Sherwood, Model 410).
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Histological assessment
The tissue samples from the liver, kidney and heart for
histological examination were passed through the
process of fixation, dehydration, clearing, infiltration,
embedding, sectioning and staining. To ensure good fix-
ation, the tissues were trimmed to about 5 mm thick-
ness, so as to obtain good fixation. The tissues were
then fixed in 10 % formol saline and were then trans-
ferred to 50 % alcohol (70 %, 80 %, 85 %, 95 and 100 %),
for two hours. Alcohol was removed from the treated
tissues by titrating them through first an equal mixture
100 % (absolute) alcohol and xylene for one hour each
in that order. Infiltration was carried out twice by pass-
ing each tissue through molten paraffin wax in an oven
at a temperature of 30 °C for one and a half hours each.
The tissues so embedded in molten paraffin wax were
later placed on a wooden block and trimmed to size.
Serial sections 10μm thick were made using a rotatory
microtome. The cut sections were then floated in a warm
water bath at a temperature of 30 - 40 °C and were placed
slides. Eight sections were obtained from each treated
organ from each animal. Four samples were placed on
each slide. Microscopic examination was done by using
varying magnifications of 10, 40, 100 and 400 to determine
if the samples were properly fixed on the slides. Following
staining, mounting of sections was carried out using di-
methyl paraffinate xylene (DPX) as a mounting agent,
after which microscopic examination was done.
Statistical analysis of data
All data were expressed as mean ± standard error of mean
(SEM). Significant differences among the group were
determined by one-way analysis of variance (ANOVA)
and Post hoc testing was performed for inter-group com-
parisons for least significant difference (LSD) [46] using
the statistical analysis programme for social sciences
(SPSS). Graphs were plotted using GraphPad Prism 6. Re-
sults were considered to be significant at p ≤ 0.05.
Results
Acute oral toxicity test
Table 1 shows the results of acute oral toxicity testing of
BSC administered at graded doses of 250, 500, 1000,
2000 and 4000 mg/kg respectively. The animals showed
no mortality at the doses given. There were also no toxic
changes observed with 250 mg/kg while doses of
500 mg/kg and above manifested reduced locomotion,
mild scratching of the lower jaw and initial slight hyper-
activity followed by weakness in treated mice when com-
pared with control group in first two hours post
treatment.
Acute intraperitoneal toxicity test
Table 2 shows the acute i.p. toxicity testing of BSC.
Here, we observed mortality or toxic changes in mice
administered with BSC at doses of 200, 400, 800 and
1600 mg/kg respectively. At 200 mg/kg (i.p.) of BSC,
animals showed signs of agitation, climbing, gripping,
hyperphagia, leaning on hind limbs, and circular move-
ments. Doses of 400 mg/kg and above showed signs of
restlessness, weakness, flattened the abdomen, tears, and
increased shallow breathing after 2 h of administration.
And at about 6th–10th hour, most animals shivered. We
obtained a mean lethal dose (LD50) of 600 mg/kg.
Table 1 Effects of acute oral toxicity study after 24 h of administration of Bon-santé cleanser® in mice
Treatments D/TK Sign of toxicity
Control (Distilled water, 0.1 ml p.o) 0/5 No toxic changes observed
BSC (250 mg/kg, p.o) 0/5 No toxic changes observed
BSC (500 mg/kg, p.o) 0/5 Mild scratching of lower jaw was observed in at least 3 animals in first 2 h
BSC (1000 mg/kg, p.o) 0/5 Slight hyperactive, scratching of lower jaw and weakness in at least 3 animals in first 2 h
BSC (2000 mg/kg, p.o) 0/5 Slight hyperactive, scratching of lower jaw and weakness in at least 3 animals in first 2 h
BSC (4000 mg/kg, p.o) 0/5 Slight hyperactive, scratching of lower jaw and weakness in at least 3 animals in first 2 h
BSCC Bon-santé® cleanser capsule, KD/T Number of mice death/Total number of mice per group (n = 5)
Table 2 Effects of acute intraperitoneal toxicity study after 24 h of administration of Bon-santé cleanser® in mice
Treatments D/TK Sign of toxicity
Control (Distilled water, 0.1 ml i.p) 0/6 No toxic changes observed
BSC (200 mg/kg, i.p) 0/6 No toxic changes observed
BSC (400 mg/kg, i.p) 2/6 Slight weakness observed in at least 3 animals in first 2 h.
BSC (800 mg/kg, i.p) 6/6 Slight weakness observed in at least 3 animals in first 2 h.
BSC (1600 mg/kg, i.p) 6/6 Slight weakness observed in at least 3 animals in first 2 h.
BSC Bon-santé cleanser®, KD/T Number of mice death/Total number of mice per group (n = 6). Acute Lethal Dose (LD50) = 600 mg/kg
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Liver function
Table 3 shows that the levels of serum alanine amino-
transferase (ALT), aspartate aminotransferase (AST) and
alkaline phosphatase (ALP) did not change significantly
(p >0.05) when compared with the control group. BSC at
lowest dose (250 mg/kg) reduced ALT and ALP levels
respectively. Similarly, there was statistically insignificant
(p >0.05) dose dependent increase in AST levels when
administration BSC was administered at 250 mg/kg
(32.4 %), 500 mg/kg (39.2 %) and 1000 mg/kg (51.4 %).
ALT levels were insignificantly (p >0.05) elevated at
doses of 500 mg/kg (41.4 %) and 1000 mg/kg (29.3 %)
respectively.
Lipid profiles
BSC shows a slight reduction (p >0.05) in serum TG
levels by 11.6 %, 9.8 % and 1.5 % respectively, although,
the lowest dose of BSC (250 mg/kg) slightly elevated
serum TC levels (Table 4). Serum low density lipopro-
tein (LDL) was insignificantly (p >0.05) lowered by
14.7 % and 4.6 % at doses of 250 mg/kg and 500 mg/kg.
BSC (1000 mg/kg) slightly elevated LDL by 28.5 %
(p >0.05).
Renal function, protein synthesis and uric acid
Blood Urea Nitrogen levels was increased by
11.8 %(p >0.05) and 13.7 %(p >0.05) at 500 mg/kg and
1000 mg/kg respectively as shown in Table 5. BSC
(250 mg/kg) also elevated Creatinine levels by 7.1 %
(p >0.05), but, did not significant alter serum albumin
(ALB), total protein (TP) and UA respectively in all sub-
jects. But, BSC doses of 500 mg/kg and 1000 mg/kg,
produced insignificantly (p >0.05) elevated levels of ALB,
TP, and UA in the treated rats.
Haematological assessments
BSC shows elevated packed cell volumes at 250 mg/kg
(p >0.05) and 500 mg/kg (p <0.05) respectively (Table 6).
Similarly, heamoglobin levels were insignificantly (p >0.05)
when compared with control as well. BSC increased TWBC
at 250 mg/kg by 62.6 % (p <0.05) and platelets count by
50.6 % (p >0.05) when administered at 500 mg/kg.
Serum electrolytes
BSC causes a dose related insignificantly increased Na+
following oral administration from 250 mg/kg through
1000 mg/kg (Table 7). iCa2+ levels was decreased at
250 mg/kg(p >0.05) while it increased(p >0.05) at the mid-
dle and highest doses respectively. The serum K+, Cl− and
tCa2+ levels were unaltered in animals.
Tissue proteins
Figure 1, BSC produces an increased in the levels of hep-
atic TP, although, insignificantly (p >0.05). No difference
was observed in renal, brain and heart TP levels respect-
ively in all subjects when compared with control group
(p >0.05).
Lipid peroxidation
BSC at doses of 250 mg/kg, 500 mg/kg and 1000 mg/kg
shows reduced (P >0.05) hepatic and brain LPO (Malon-
dialdehyde, MDA) (Fig. 2). Similarly, low (250 mg/kg) and
highest (1000 mg/kg) doses also reduced renal MDA
(P >0.05). BSC (500 mg/kg) shows slight elevation
(P >0.05) in MDA levels. Both 250 mg/kg and 500 mg/kg
doses elevated MDA levels in heart, although, insignifi-
cantly when compared with control (p >0.05).
Tissue anti-oxidants
Hepatic antioxidants
BSC shows at low (250 mg/kg) and highest (1000 mg/kg)
doses an increased (p <0.05) hepatic GSH levels by 68 %
and 49.2 % respectively (Fig. 3). No observable statistical
difference in GST, superoxide dismutase and the control.
But, a 1000 mg/kg of BSC indicated elevated hepatic CAT
levels by 54.1 % (p <0.05).
Table 3 Effects of subchronic administration of Bon-santé
cleanser® on liver function in male rats
Treatments ALT (Units/L) AST (Units/L) ALP (Units/L)
Control (DW, 10 ml/kg) 20.50 ± 3.95 18.50 ± 0.95 38.00 ± 2.94
BSC (250 mg/kg) 18.50 ± 2.99 24.50 ± 5.56 37.50 ± 2.33
BSC (500 mg/kg) 29.00 ± 4.04 25.75 ± 3.88 35.50 ± 5.44
BSC (1000 mg/kg) 26.50 ± 3.10 25.00 ± 3.70 40.25 ± 2.25
Note: Result expressed as mean ± SEM
BSC Bon-santé cleanser®, DW Distilled water (10 ml/kg), ALT Alanine
Aminotransferase, AST Aspartate Aminotransferase, ALP Alkaline Phosphatase
Table 4 Effects of subchronic administration of Bon-santé cleanser® on serum lipids levels in male rats
Treatments TC (mg/dl) TG (mg/dl) HDL (mg/dl) LDL (mg/dl)
Control (DW) 91.00 ± 8.19 120.50 ± 9.50 27.00 ± 1.58 58.70 ± 8.90
BSC (250 mg/kg) 99.25 ± 9.25 106.50 ± 8.73 27.75 ± 3.90 50.05 ± 9.38
BSC (500 mg/kg) 117.00 ± 9.25 108.67 ± 16.22 25.50 ± 1.32 56.00 ± 7.40
BSC (1000 mg/kg) 112.50 ± 7.54 118.67 ± 17.46 27.50 ± 1.76 75.40 ± 6.60
Note: Result expressed as mean ± SEM
BSC Bon-santé cleanser®, DW Distilled water (10 ml/kg), TC Total Cholesterol, TG Triglyceride, HDL High Density Lipoprotein, LDL Low Density Lipoprotein
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Renal antioxidants
There were increased GSH levels in the kidneys at high-
est BSC dose (1000 mg/kg) used in this present study
(Fig. 4). However, renal GST levels decreased given all
administered doses of BSC. Only the lowest dose
(250 mg/kg) shows increased CAT levels. On the other,
both 250 mg/kg and 500 mg/kg elevated renal SOD
levels but insignificant (p >0.05).
Heart antioxidants
BSC highest dose (1000 mg/kg) produces elevated heart
GSH levels by 9.7 % and decreases (p <0.05) heart GST
levels in treated rats by 54 % (Fig. 5). In addition, CAT
levels increased in the heart at 500 mg/kg and 1000 mg/kg
(p >0.05). There were decreased (p <0.05) SOD levels in the
heart of treated rats, in a dose related manner by 30.1 %
(250 mg/kg), 40.5 % (500 mg/kg) and 39.1 % (1000 mg/kg)
respectively.
Brain antioxidants
An administration of BSC at doses used in this study
produces a dose dependent increased (p <0.05) in brain
GSH levels by 18.8 %, 96.4 % and 212.3 % respectively
(Fig. 6). More so, BSC at 250 mg/kg shows a decreased
brain GST levels in the treated animals (p <0.05). Brain
CAT levels was also elevated (p <0.05) given 500 mg/kg
and 1000 mg/kg respectively. However, there was a de-
crease (p >0.05) in brain SOD levels in the treated rats.
Body and organ system weights
The effects of sub-chronic administration of BSC on body
weights in male rats administered with 250 mg/kg and
1000 mg/kg were not significantly (p >0.05) different from
those of control groups (Fig. 7). However, only 500 mg/kg
of BSC ably increased (p <0.05) body weights. And simi-
larly, a 1000 mg/kg reduced (p <0.05) heart as well.
Histological assessments
Control group (Distilled Water, 10 ml/kg)
Figure 8: Control (Distilled Water, 10 ml/kg, A) and
BSC (250 mg/kg, B; 500 mg/kg, C) showed normal heart.
However, BSC (1000 mg/kg, D) shows dense aggregates
inflammatory heart (see arrow). (H & E stain, Mag.
X400). (BSC = Bon-santé cleanser®).
BSC (250 mg/kg)
Figure 9: Control (Distilled Water, 10 ml/kg, E) and BSC
(250 mg/kg, F; 500 mg/kg, G; 1000 mg/kg, H) showed nor-
mal kidney (H & E stain, Mag. X400). (BSC = Bon-santé
cleanser®).
Table 5 Effects of subchronic administration of Bon-santé cleanser® on renal function, serum albumin, total protein and uric acid
levels in male rats
Treatments Control BSC BSC BSC
(DW) (250 mg/kg) (500 mg/kg) (1000 mg/kg)
UREA (U/L) 9.35 ± 1.74 8.88 ± 1.95 10.43 ± 2.68 10.63 ± 1.33
CREATININE (U/L) 0.28 ± 0.05 0.30 ± 0.04 0.28 ± 0.03 0.28 ± 0.03
ALB (mg/dl) 4.43 ± 0.39 4.05 ± 0.31 5.10 ± 0.29 4.55 ± 0.24
TP (mg/dl) 8.98 ± 0.74 8.73 ± 0.63 9.43 ± 0.77 9.55 ± 0.25
UA (mg/dl) 9.35 ± 1.74 8.88 ± 1.95 10.43 ± 2.68 10.63 ± 1.33
Note: Result expressed as mean ± SEM
BSC Bon-santé cleanser®, ALB Albumin, TP Total Protein, UA Uric Acid
Table 6 Effects of subchronic administration of Bon-santé
cleanser® on hematological parameters in male rats
Treatments Control BSC BSC BSC
(DW) (250 mg/kg) (500 mg/kg) (1000 mg/kg)
PCV 31.8 ± 2.7 35.8 ± 1.7 40.0 ± 1.2* 26.5 ± 4.1
Hb 10.8 ± 1.0 12.5 ± 0.5 13.4 ± 0.4 10.0 ± 1.2
PLT (x109/L) 293.8 ± 67.2 235.0 ± 48.6 442.5 ± 29.5 171.3 ± 21.1
TWBC (x109/L) 4.8 ± 1.2 7.8 ± 1.4 3.6 ± 0.6 3.9 ± 0.3
Note: Result expressed as mean ± SEM
BSC Bon-santé cleanser®, DW Distilled water (10 ml/kg), PCV% Packed Cell Volume,
Hb Hemoglobin, PLTx109 Platelet, TWBC Total White Blood Cell Count
*p <0.05 when compared with control group
Table 7 Effects of subchronic administration of bon-santé
cleanser® on serum electrolytes in male rats
TREATMENTS Control BSC BSC BSC
(DW) (250 mg/kg) (500 mg/kg) (1000 mg/kg)
Na+ 16 .8 ± 1.3 23.9 ± 5.0 25.5 ± 5.6 23.9 ± 3.8
K+ 135.1 ± 0.9 143.2 ± 18.4 128.9 ± 8.0 126.5 ± 3.8
Cl− 98.8 ± 0.8 94.2 ± 0.9 96.2 ± 1.6 96.9 ± 1.2
tCa2+ 2.41 ± 0.0 2.21 ± 0.1 2.34 ± 0.1 2.32 ± 0.1
iCa2+ 1.24 ± 0.02 1.08 ± 0.02* 1.17 ± 0.04 1.19 ± 0.04
Note: Result expressed as mean ± SEM. b: mmol/L
BSC Bon-santé cleanser®, DW Distilled water (10 ml/kg), Na+ Sodium ion, K+
Potassium ion, Cl− Chloride ion, tCa+ total Calcium ion, iCa2+ intracellular
Calcium ion
*p <0.05 when compared with control group
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BSC (500 mg/kg)
Figure 10: Control (Distilled Water, 10 ml/kg, I). BSC
(250 mg/kg, J; 500 mg/kg, K) showed normal liver. But,
BSC (1000 mg/kg, L) shows congestion of the hepatic
sinusoids and the central vein (see arrow). (H & E stain,
Mag. X400). (BSC = Bon-santé cleanser®).
Discussions
There is a new global interest in the use of alternative
means of maintaining and healing sick people [47]. The
WHO fact sheet (No.134) estimates that about 80 % of
the populations in African and Asian countries rely on
traditional medicine for their primary healthcare [48]. It
also recognizes traditional medicine as ‘an accessible, af-
fordable and culturally acceptable form of healthcare
trusted by large numbers of people, which stands out as
a way of coping with the relentless rise of diseases in the
midst of soaring health-care costs and nearly universal
austerity [47]. There are many reasons for this new
phenomenon. The first is that many of the producers de-
scribe multifaceted great healing properties to these al-
ternative means [5, 6, 49]. The second is that they
propose that these therapies are natural and so have less
or little side effects [5, 50]. Finally because of poverty
and the inability to pay for some of the western medi-
cines that have verifiable efficacies many patients turn to
herbal medicines. Unfortunately, there are evidence to
show that the majority of these herbal medicines have
not been as well screened for efficacy and toxicity when
compared to their western counterparts [1, 51]. As tox-
icity studies and scientific investigations into these
Fig. 1 Effects of Bon-santé cleanser® (BSC) on tissue total protein in
normal male rats. Result expressed as mean± SEM; Control: (DW,
Distilled water)
Fig. 2 Effects of Bon-santé cleanser® (BSC) on lipid peroxidation in
normal male rats. Result expressed as mean ± SEM. DW: Distilled
water (10 ml/kg). LPO: Lipid Peroxidation (ie Malondialdehyde)
Fig. 3 Effects of Bon-santé cleanser® (BSC) on hepatic antioxidants in
normal male rats. Result expressed as mean ± SEM. DW: Distilled water
(10 ml/kg); GSH: Reduced Glutathione (μmol/mg protein); CAT: Catalase
(μmol/ml/mg protein); SOD: Superoxide Dismutase Activity (μmol/min/
mg protein); GST: Glutathione-S-Transferase (μmol/ml/min)
Fig. 4 Effects of Bon-santé cleanser® (BSC) on renal antioxidants in
normal male rats. Result expressed as mean ± SEM. *p <0.05 when
compared with control group. DW: Distilled water (10 ml/kg); GSH:
Reduced Glutathione (μmol/mg protein); CAT: Catalase (μmol/ml/mg
protein); SOD: Superoxide Dismutase Activity (μmol/min/mg protein);
GST: Glutathione-S-Transferase (μmol/ml/min)
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herbal remedies are often expensive [52], it is now left to
the scientific community to investigate some of the
claims of the manufacturers of these herbal preparations
to verify or refute their claims. This is an important pub-
lic health service that must not be overlooked if it is
really true that academics must contribute to safeguard-
ing the health of our people.
In view of the foregoing, scientific investigations of alter-
native means to healthcare are now focusing on safety and
toxicological evaluation of herbal formulation [53–55].
Our group decided to study BSC for the following reasons.
BSC contains A. lerocarroa, T. accularia, M. accuminata
and M. pruiens formulated into a capsule. Several authors
at different times have contributed to the elucidation of
the chemical compositions of the individual component of
the popular BSC. Also, The chemical compositions and
hypotheses on folklore medicine uses of these plants have
been well documented [17–21, 23–28, 56]. However, some
investigators have shown that there is potential to aug-
ment the individual toxicities in herbal preparations when
mixed [5, 6, 8, 55, 57–59]. To the best of our knowledge,
not much is known in the literature with respect to the
toxicity of the components of the herbs contained in the
BSC capsule. Thus, there is rational in carrying out toxico-
logical studies on this herbal preparation as it is on the
open market, and the manufacturers claim they have
many clients. Therefore, we investigated the Safety evalu-
ation of BSC when ingested orally in male Wistar rats.
The determination of acute toxicity testing is usually a
step ab inicio in the assessment and evaluation of the
toxic characteristics of a substance [60]. Our results
show that when BSC is given orally, the herbal prepar-
ation was relatively safe as there was no mortality during
the acute toxicity tests. This is an important finding as
the major route of administration of herbal medicines is
oral. The acute oral and intraperitoneal LD50 in mice
were >4000 mg/kg and 600 mg/kg respectively.
Nevertheless, there were small but statistically insig-
nificant changes in serum liver and renal enzymes as
well as serum electrolytes (Tables 3, 5 and 7). Whether
this will later translate into outright hepatic and renal
damage with the chronic administration is very hard to
tell. One important outcome of this study is the increase
in PCV (Table 6) and decrease in LDL (Table 4) with
oral administration. While these results may look ex-
citing, it is too early to determine whether BSC could
be deployed as a lipid modulating remedy either on
its own or as an adjunct to well-known compounds
Fig. 5 Effects of Bon-santé cleanser® (BSC) on heart antioxidants in normal
male rats. Result expressed as mean± SEM. #p<0.05 and *p<0.001 when
compared with control group. DW: Distilled water (10 ml/kg);
GSH: Reduced Glutathione (μmol/mg protein); CAT: Catalase
(μmol/ml/mg protein); SOD: Superoxide Dismutase Activity (μmol/min/
mg protein); GST: Glutathione-S-Transferase (μmol/ml/min)
Fig. 6 Effects of Bon-santé cleanser® (BSC) on brain antioxidants in
normal male rats. Result expressed as mean ± SEM. *p <0.05 when
compared with control group. DW: Distilled water (10 ml/kg); GSH:
Reduced Glutathione (μmol/mg protein); CAT: Catalase (μmol/ml/mg
protein); SOD: Superoxide Dismutase Activity (μmol/min/mg protein);
GST: Glutathione-S-Transferase (μmol/ml/min)
Fig. 7 Effects of Bon-santé cleanser® (BSC) on organ system body
weight in normal male rats. Result expressed as mean ± SEM. *p <0.05
when compared with control group. DW: Distilled water (10 ml/kg);
LVW: Liver weight; KDW: Kidney weight; BRW: Brain weight; HW: Heart
weight; LGW: Lungs weight
Kale and Awodele BMC Complementary and Alternative Medicine  (2016) 16:188 Page 8 of 12
that carry out this role in the health system. No histo-
logical changes following a subchronic oral administration
were seen on the kidneys unlike mild to moderate alter-
ations that were observed in the liver and heart when the
highest dose (1000 mg/kg) was administered (Figs. 8, 9
and 10). However, the limitation of our study lies in the
duration since a chronic toxicity evaluation of BSC would
be necessary in order to comment on the long-term
outcomes.
Since there have been suggestions that botanicals,
when used alone or in combination with other
medications, could precipitate severe organ system tox-
icity [61]. Our observation is that treatment with differ-
ent doses of BSC did not result in predictable changes
with graded doses (Tables 3, 4, 5, 6, and 7 & Figs. 1, 2, 3,
4, 5, and 6). Thus, there is a lot of cautions to be
expressed in humans as our study indicate altered levels
of hepatic biomarkers and some antioxidants, though, it
does not pinpoint the part of departure between dose
and biochemical outcomes. More so, there was a small
improvement in lipid profile at low doses. Thus, at this
stage, it could be suggested that further observations be
Fig. 8 Control (Distilled Water, 10ml/kg) shows normal heart muscle (a). BSC (250mg/kg) shows normal heart (b). BSC (500mg/kg) shows normal
heart (c). BSC (1000mg/kg) shows dense aggregates inflammatory heart (d) (see arrow). (H & E stain, Mag. X400). BSC= Bon-santé cleanser®
Fig. 9 Control (Distilled Water, 10ml/kg) shows normal kidney (e). BSC (250mg/kg) shows normal kidney (f). BSC (500mg/kg) shows normal
kidney (g). BSC (1000mg/kg) shows normal kidney (h) (H & E stain, Mag. X400). (BSC= Bon-santé cleanser®)
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made in humans who have consumed the medicine in
the past to verify its usefulness and comments on side
effects.
Conclusion
BSC has been found to be relatively safe in Wistar rats.
Although, our findings indicate that herbal therapy with
BSC should be done with caution as a mild alteration in
the liver and heart architectures were observed.
Abbreviations
BSC, Bon-santé cleanser®; ED50, Mean Effective Dose; LD50, Mean Lethal Dose
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